Action
Monoclonal antibody (humanized) against the neutrophil CD11/CD18 cell adhesion molecule.

Status
Phase 2 trial of 48 patients reported that drug was safe. Phase 3 trial in acute stroke initiated 1/99, halted as of 4/20/00. "Interim results of a Phase III study of LeukArrest in patients who have had an ischemic stroke failed to meet predefined criteria for success."

Trial(s)
  = Ongoing
  = Completed

HALT

Hu23F2G Phase 3 stroke trial

UID: 26